Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mette K Nedergaard

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 6, 2012
Targeting the epidermal growth factor receptor in solid tumor malignanciesMette K Nedergaard, Chris J Hedegaard, Hans S Poulsen
Plos One|June 12, 2014
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenograftsMette K Nedergaard, Karina Kristoffersen, Signe R Michaelsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2015
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in GlioblastomaMorten Persson, Mette K Nedergaard, Malene Brandt-Larsen, et al.
Neuro-Oncology|June 26, 2018
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenanceSigne R Michaelsen, Mikkel Staberg, Henriette Pedersen, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 6, 2012
Targeting the epidermal growth factor receptor in solid tumor malignanciesMette K Nedergaard, Chris J Hedegaard, Hans S Poulsen
Plos One|June 12, 2014
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenograftsMette K Nedergaard, Karina Kristoffersen, Signe R Michaelsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2015
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in GlioblastomaMorten Persson, Mette K Nedergaard, Malene Brandt-Larsen, et al.
Neuro-Oncology|June 26, 2018
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenanceSigne R Michaelsen, Mikkel Staberg, Henriette Pedersen, et al.
Pageof 1